Article content
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the first patients have been dosed in the Phase III ZIRCON
1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (
89Zr-girentuximab) in the United States.
The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth.
The ZIRCON trial, which includes twelve participating clinical study sites across the U.S. and Canada, initiated patient recruitment in U.S. on Friday, with the first patients being dosed with TLX250-CDx at University of California, Los Angeles (UCLA), and Seattle Cancer Care Alliance, University of Washington, Seattle (SCCA)
In March of 2020, during the first U.S. surge of the COVID-19 pandemic, MedPage Today
published a story on oncology specialists from the Seattle Cancer Care Alliance (SCCA) who shared their early clinical experience in adapting patient care to the challenges posed by the pandemic. In this follow-up, we update information on the current status of cancer care delivery and additional steps taken to protect patients and providers.
Recognized as the first U.S. epicenter of the COVID-19 pandemic, the metropolitan Seattle area provided early leadership in developing strategies to limit the spread of the infection. The SCCA followed suit by implementing protocols to balance the need to maintain essential oncology services against the paramount issue of providing maximum safety for vulnerable patients with cancer, as well as healthcare providers. At the time, data from China indicated that patients with cancer and COVID-19 had a three to four times greater risk of mechanical ventilation,
This story was originally published on March 25, 2020. As part of MedPage Today s review of top stories in 2020, we are republishing it, along with an update on the COVID-19 pandemic s impact on cancer care within the Seattle Cancer Care Alliance, reviewing subsequent developments since.
While having an unprecedented impact on all aspects of the nation s healthcare system, the COVID-19 pandemic created unique circumstances and challenges for cancer care, according to authors of a review from the early U.S. epicenter in metropolitan Seattle.
The first confirmed U.S. case of COVID-19 was reported on Jan. 20 in Snohomish County, about an hour north of Seattle. The first COVID-19 death in the country occurred there, as well.
®) put out new information today to provide guidance for COVID-19 vaccinations in people with cancer. The nonprofit alliance of leading cancer centers created an NCCN COVID-19 Vaccine Committee that includes top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, medical ethics, and health information technology. These recommendations can help cancer care providers make informed decisions on how to protect their patients from the ongoing COVID-19 pandemic, based on available evidence plus expert consensus. The committee s recommendations state that all people currently in active cancer treatment should get the vaccine, with some advice to consider regarding immunosuppression and timing. The full document can be found at NCCN.org/covid-19, along with other vital information about the impact of COVID-19 on cancer care.
Cancer patients and the COVID-19 vaccines
Clinicians, cancer patients and coronavirus researchers weigh in on vaccination safety, timing, allergy concerns and more January 14, 2021 • By Diane Mapes / Fred Hutch News Service Metastatic breast cancer patient and family doctor Dr. Carla Kakuta of Winters, California, receives her first COVID-19 shot, before heading off to cancer treatment. I went straight from vaccination to the infusion center because I’m awesome like that, she wrote on Twitter. “I ve been seeing patients in person through the pandemic. Since Thanksgiving the % positive rate of the people I test has been 15 to 20%. Grateful I’ve been able to avoid bringing it home to my family.